TP53 and B-cell chronic lymphocytic leukemia: The gold standard in CLL prognostication, CLL-IPI3, had the following availability in its five variables (age: 100%, Binet Stage: 17.8%, β2 microglobulin: 64.8%, IGHV status: 18.9%, Del17p and/or TP53 mutation: <0.05%).